MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$537,957K
Net loss
attributable to common...
-$537,957K
Molecular Profiling
Services
$766,719K
Pharma Research And
Development Services
$45,314K
Deemed dividend from
series d redeemable...
$384,436K
Adjustments of redeemable
convertible preferred stock...
$85,433K
Net loss
-$68,088K
Total revenue
$812,033K
Loss before income
taxes and provision...
-$68,088K
Income (loss) from
operations
$45,113K
Total costs and
operating expenses
$766,920K
Total other expense,
net
-$113,201K
Interest income
$16,497K
Cost of
services-Molecular Profiling...
$262,353K
General and
administrative expense (see...
$224,965K
Selling and marketing
expense
$167,506K
Research and development
expense
$101,584K
Interest expense
$56,853K
Changes in fair value of
financial instruments
-$52,285K
Other expense, net
-$20,560K
Back
Back
Income Statement
source: myfinsight.com
Caris Life Sciences, Inc. (CAI)
Caris Life Sciences, Inc. (CAI)